Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration

Article Abstract Objective: This study aimed to examine the degree of clinical and functional improvement after paliperidone long-acting injectable (LAI) administration according duration illness. Methods: Patients with schizophrenia diagnosed by ICD-10 criteria who were planned start once-monthly LAI recruited from 2010 2017. Clinical changes measured every 4 weeks using Global Impressions-Severity Illness scale (CGI-S) Personal Social Performance (PSP), respectively, for 6 months initiation. Improvements starting compared among patients illness < 3 years, ≥ 10 years. Results: A total 1,166 participants (duration n = 240; ≤ 442; 484) enrolled. The olanzapine-equivalent doses antipsychotics monotherapy proportion at final visit significantly different groups (dose: F2,1163 18.41, P .001; monotherapy: χ22 11.73, .003). in CGI-S score illness, those years showed best (group × week: χ212 25.33, .013). All improved PSP scores (week: χ26 294.2, .001). Conclusions: Starting outcomes schizophrenia, especially shorter These findings suggest that antipsychotic may be considered early-stage outcomes.